-
Income Statement
-
Balance Sheet
-
Cashflow Statement
-
Profitability
-
Ratios
Amgen Income Statement
| Chart | 2020 | 2021 | 2022 | 2023 | |
|---|---|---|---|---|---|
| Revenue |
|
$25.42B | $25.98B | $26.32B | $28.19B |
| Cost of Revenue |
|
$6.16B | $6.45B | $6.41B | $8.42B |
| Gross Profit |
|
$19.27B | $19.53B | $19.92B | $19.78B |
| Research & Development |
|
$4.21B | $4.82B | $4.43B | $4.78B |
| Selling,General & Administrative |
|
$5.73B | $5.37B | $5.41B | $6.18B |
| Operating Expense |
|
$10.13B | $10.38B | $10.35B | $11.88B |
| Operating Income |
|
$5.79B | $6.01B | $5.34B | $7.90B |
| Net Income |
|
$7.26B | $5.89B | $6.55B | $6.72B |
Amgen Balance Sheet
| Chart | 2020 | 2021 | 2022 | 2023 | |
|---|---|---|---|---|---|
| Cash and Cash Equivalents |
|
$10.65B | $8.04B | $9.31B | $10.94B |
| Inventories |
|
$3.89B | $4.09B | $4.93B | $9.52B |
| Total Current Assets |
|
$21.14B | $19.39B | $22.19B | $30.33B |
| Property,Plant and Equipment |
|
$4.89B | $5.18B | $5.43B | $6.59B |
| Goodwill |
|
$14.69B | $14.89B | $15.53B | $18.63B |
| Total Assets |
|
$62.95B | $61.17B | $65.12B | $97.15B |
| Total Liabilities |
|
$53.54B | $54.47B | $61.46B | $90.92B |
| Retained Earnings |
|
-$21.41B | -$24.60B | -$28.62B | -$26.55B |
| Total Shareholder Equity |
|
$9.41B | $6.70B | $3.66B | $6.23B |
| Common Stock |
|
$31.80B | $32.10B | $32.51B | $33.07B |
Amgen Cash flow
| Chart | 2020 | 2021 | 2022 | 2023 | |
|---|---|---|---|---|---|
| Depreciation & Amortization |
|
$3.60B | $3.40B | $3.42B | $4.07B |
| Dividends Payout |
|
-$3.76B | -$4.01B | -$4.20B | -$4.56B |
| Capital Expenditures (Capex) |
|
-$608.00M | -$880.00M | -$936.00M | -$1.11B |
| Free Cash Flow (FCF) |
|
$9.89B | $8.38B | $8.79B | $7.36B |
Amgen Profitability
| Chart | 2020 | 2021 | 2022 | 2023 | |
|---|---|---|---|---|---|
| Gross Profit |
|
$19.27B | $19.53B | $19.92B | $19.78B |
| Gross Profit Margin (%) |
|
75.77% | 75.16% | 75.66% | 70.15% |
| Operating Income |
|
$5.79B | $6.01B | $5.34B | $7.90B |
| Operating Income Margin (%) |
|
22.79% | 23.11% | 20.27% | 28.01% |
| Net Income |
|
$7.26B | $5.89B | $6.55B | $6.72B |
| Net Income Margin (%) |
|
28.57% | 22.68% | 24.89% | 23.83% |
| EBITDA |
|
$12.93B | $12.54B | $12.09B | $14.70B |
| EBITDA Margin (%) |
|
36.95% | 36.19% | 33.25% | 52.15% |
Amgen Ratios
| Chart | 2020 | 2021 | 2022 | 2023 | |
|---|---|---|---|---|---|
| Return on Equity (ROE) |
|
77.20% | 87.96% | 178.97% | 107.78% |
| Return on Assets (ROA) |
|
11.54% | 9.63% | 10.06% | 6.91% |
| Debt to Equity |
|
350.58% | 497.15% | 1,063.78% | 1,036.79% |
| Debt to total asset |
|
52.40% | 54.46% | 59.80% | 66.51% |
| Enterprise value to revenue |
|
6.35 | 5.91 | 6.56 | 7.37 |
| Enterprise value to EBITDA |
|
12.49 | 12.24 | 14.27 | 14.13 |
| Enterprise value |
|
$161.45B | $153.55B | $172.62B | $207.76B |
| Cash to Debt |
|
31.82% | 27.80% | 24.96% | 13.11% |
| Tax Rate (%) |
|
10.68% | 12.06% | 10.81% | 14.49% |
| Payout Ratio |
|
51.69% | 68.10% | 64.04% | 67.83% |
Related company
